Related references
Note: Only part of the references are listed.EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2013
Marko Babjuk et al.
EUROPEAN UROLOGY (2013)
Phase I Trial of Intravesical Recombinant Adenovirus Mediated Interferon-α2b Formulated in Syn3 for Bacillus Calmette-Guerin Failures in Nonmuscle Invasive Bladder Cancer
Colin P. N. Dinney et al.
JOURNAL OF UROLOGY (2013)
Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guerin
Colin P. N. Dinney et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2013)
Treatment Options Available for Bacillus Calmette-Guerin Failure in Non-muscle-invasive Bladder Cancer
David R. Yates et al.
EUROPEAN UROLOGY (2012)
Paclitaxel-Hyaluronic Acid for Intravesical Therapy of Bacillus Calmette-Guerin Refractory Carcinoma In Situ of the Bladder: Results of a Phase I Study
P. F. Bassi et al.
JOURNAL OF UROLOGY (2011)
A Phase I Trial of Intravesical Nanoparticle Albumin-Bound Paclitaxel in the Treatment of Bacillus Calmette-Guerin Refractory Nonmuscle Invasive Bladder Cancer
James M. McKiernan et al.
JOURNAL OF UROLOGY (2011)
Contemporary management of patients with high-risk non-muscle-invasive bladder cancer who fail intravesical BCG therapy
D. R. Yates et al.
WORLD JOURNAL OF UROLOGY (2011)
Risk Factor Analysis in a Contemporary Cystectomy Cohort Using Standardized Reporting Methodology and Adverse Event Criteria
Robert S. Svatek et al.
JOURNAL OF UROLOGY (2010)
Long-term Efficacy of Maintenance Bacillus Calmette-Guerin versus Maintenance Mitomycin C Instillation Therapy in Frequently Recurrent TaT1 Tumours without Carcinoma In Situ: A Subgroup Analysis of the Prospective, Randomised FinnBladder I Study with a 20-Year Follow-up
Riikka Jarvinen et al.
EUROPEAN UROLOGY (2009)
Defining Early Morbidity of Radical Cystectomy for Patients with Bladder Cancer Using a Standardized Reporting Methodology
Ahmad Shabsigh et al.
EUROPEAN UROLOGY (2009)
Combined Thermo-Chemotherapy for Recurrent Bladder Cancer After Bacillus Calmette-Guerin
Ofer Nativ et al.
JOURNAL OF UROLOGY (2009)
Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy
James M. McKiernan et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Phase II trial of intravesical gemcitabine in bacille Calmette-Guerin-refractory transitional cell carcinoma of the bladder
G Dalbagni et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: A meta-analysis of the published results of randomized clinical trials
RJ Sylvester et al.
JOURNAL OF UROLOGY (2005)
Intravesical Ad-IFNα causes marked regression of human bladder cancer growing orthotopically in nude mice and overcomes resistance to IFN-α protein
WF Benedict et al.
MOLECULAR THERAPY (2004)
Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1,054 patients
JP Stein et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Share Paper
